CSII - カ―ディオバスキュラ―・システムズ (Cardiovascular Systems Inc.) カ―ディオバスキュラ―・システムズ



symbol CSII
会社名 Cardiovascular Systems Inc (カ―ディオバスキュラ―・システムズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 カーディオバスキュラー・システムズ(Cardiovascular Systems Inc.)は、医療技術会社であり、動脈カルシウムを含む末梢・冠動脈疾患に罹患する患者の治療に従事する。同社は、末梢・冠状動脈の両方の商用アプリケーションに、軌道アテローム切除技術を開発する。末梢動脈疾患(PAD)システムは、膝の上下の脚動脈におけるプラークタイプを治療できるカテーテルベースのプラットフォームである。同社の主力製品には、「Diamondback 360 Peripheral Orbital Atherectomy System」(OAS) (Diamondback 360 Peripheral)、「Stealth 360 OAS」(Stealth 360)、「Diamondback 360 Peripheral」、「Diamondback 360 60cm Peripheral」、「Diamondback 360 Low Profile Peripheral」、「Diamondback 360 1.50 Peripheral」及び「Diamondback 360 2.00 Peripheral」がある。同社の冠状動脈疾患(CAD)製品である「Diamondback 360 Coronary OAS」(Coronary OAS)は、重度石灰化冠状動脈の治療薬として販売される。   カ―ディオバスキュラ―・システムズは、米国の医療機器メ―カ―。血管疾患のためのインタ―ベンション治療システムの開発と商業化に焦点を当てる。末梢動脈疾患の製品、ステルス360パッドシステム、ダイヤ360パッドシステム、およびプレデタ―360パッドシステムは、カテ―テルベ―スのプラットフォ―ムで、脚の石灰化冠状動脈の治療法として使用される。   Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
本社所在地 1225 Old Highway 8 Northwest St. Paul MN 55112-6416 USA
代表者氏名 Scott R. Ward スコットR.ワード
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 651-259-1600
設立年月日 2000年
市場名 NASDAQ National Market System
ipoyear 1981年
従業員数 652人
url www.csi360.com
nasdaq_url https://www.nasdaq.com/symbol/csii
EBITDA EBITDA(百万ドル) 5.96400
終値(lastsale) 36.45
時価総額(marketcap) 1265033663.55
時価総額 時価総額(百万ドル) 1262.951
売上高 売上高(百万ドル) 217.04300
企業価値(EV) 企業価値(EV)(百万ドル) 1167.211
当期純利益 当期純利益(百万ドル) 1.71200
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Cardiovascular Systems Inc revenues increased 6% to $217M. Net income totaled $1.7M vs. loss of $1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Stock-based Compensation in R&D decrease of 4% to $967K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to $0.05.



   Cardiovascular Systems, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:CSII)  2022/05/05 07:02:01 Seeking Alpha
The following slide deck was published by Cardiovascular Systems, Inc.
   Cardiovascular Systems (CSII) Q3 2022 Earnings Call Transcript  2022/05/04 20:00:53 The Motley Fool
CSII earnings call for the period ending March 31, 2022.
   Cardiovascular Systems GAAP EPS of -$0.25 beats by $0.03, revenue of $56.22M misses by $1.16M  2022/05/04 11:10:37 Seeking Alpha
Cardiovascular Systems press release (CSII): FQ3 GAAP EPS of -$0.25 beats by $0.03.Revenue of $56.22M (-11.1% Y/Y) misses by $1.16M.As of March 31, 2022, CSI had cash and…
   Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results  2022/05/04 11:00:00 Business Wire
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its third quarter, ended March 31, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO “Third quarter results were in line with our expectations. Despite the impact that Omicron had on hospital capacit
   Cardiovascular Systems Q3 2022 Earnings Preview (NASDAQ:CSII)  2022/05/03 16:34:04 Seeking Alpha
Cardiovascular Systems (CSII) is scheduled to announce Q3 earnings results on Wednesday, May 4th, before market open.The consensus EPS Estimate is -$0.33 (vs
   Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026  2022/02/22 18:00:00 Benzinga
New York, USA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026 As per DelveInsight analysis, the demand for Peripheral Vascular Devices is increasing due to the rapid rise in cardiovascular and peripheral vascular diseases prevalence, as well as the approval of new and improved products by market players along with the rising frequency of lifestyle disorders such as diabetes and hypertension. DelveInsight''s Peripheral Vascular Devices Market Insights report provides the current and forecast Peripheral Vascular Devices market, upcoming device innovation, individual market shares, challenges, drivers, barriers, and market trends and key Peripheral Vascular Device companies in the market. Key Takeaways from the Peripheral Vascular Devices Market report According to DelveInsight analysis, North America is expected to dominate the Peripheral Vascular Devices market during the forecast period. Key Peripheral Vascular Device companies working in the global market are Medtronic, Boston Scientific Corporation, B.
   Cardiovascular Systems (CSII) Q2 2022 Earnings Call Transcript  2022/02/04 02:00:26 The Motley Fool
CSII earnings call for the period ending December 31, 2021.
   Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2022 Results - Earnings Call Transcript  2022/02/03 19:23:06 Seeking Alpha
   Cardiovascular Systems, Inc. 2022 Q2 - Results - Earnings Call Presentation  2022/02/03 18:21:47 Seeking Alpha
   Cardiovascular Systems GAAP EPS of -$0.23 misses by $0.09, revenue of $59.1M misses by $3.56M, cuts FY fuidance  2022/02/03 11:02:12 Seeking Alpha
Cardiovascular Systems press release (CSII): Q2 GAAP EPS of -$0.23 misses by $0.09.Revenue of $59.1M (-7.9% Y/Y) misses by $3.56M.For the fiscal year ending June 30, 2022,
   Perkins Capital Management Inc. Decreases Holdings in Cardiovascular Systems, Inc. (NASDAQ:CSII)  2021/12/09 15:50:46 Dakota Financial News
Perkins Capital Management Inc. trimmed its holdings in shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) by 56.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 21,767 shares of the medical device companys stock after selling 28,175 shares during the quarter. Perkins Capital Management Inc.s holdings in Cardiovascular Systems were worth $715,000 at the []
   Cardiovascular Systems, Inc. (NASDAQ:CSII) Expected to Announce Earnings of -$0.14 Per Share  2021/12/08 13:12:42 Dakota Financial News
Equities research analysts predict that Cardiovascular Systems, Inc. (NASDAQ:CSII) will announce earnings of ($0.14) per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Cardiovascular Systems earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.09). The company is scheduled to []
   Cardiovascular Systems, Inc. (NASDAQ:CSII) Given Consensus Rating of Hold by Analysts  2021/12/05 20:00:46 Transcript Daily
Cardiovascular Systems, Inc. (NASDAQ:CSII) has been assigned an average recommendation of Hold from the nine research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 1 []
   Cardiovascular Systems (NASDAQ:CSII) Sees Strong Trading Volume  2021/12/02 16:05:15 Transcript Daily
Cardiovascular Systems, Inc. (NASDAQ:CSII) saw unusually-strong trading volume on Thursday . Approximately 31,844 shares were traded during trading, a decline of 86% from the previous sessions volume of 230,275 shares.The stock last traded at $19.33 and had previously closed at $20.00. A number of equities research analysts have issued reports on CSII shares. SVB Leerink []
   Cardiovascular Systems Inc. (CSII) Has Great Growth Outlook For 2021  2021/12/01 12:00:00 Marketing Sentinel
Cardiovascular Systems Inc. (NASDAQ:CSII) has a beta value of 0.86 and has seen 1.0 million shares traded in the last trading session. The company, currently valued at $855.60M, closed the last trade at $20.00 per share which meant it lost -$1.11 on the day or -5.26% during that session. The CSII stock price is -141.4% Cardiovascular Systems Inc. (CSII) Has Great Growth Outlook For 2021 Read More »

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 カ―ディオバスキュラ―・システムズ CSII Cardiovascular Systems Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)